Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AssigneeUniversite Paris Est Creteil Val De Marne
InventorsSerge Adnot, Valerie Amsellem
Life of this patent
Estimating the term…
Abstract
The present invention relates to uses, methods and compositions for the treatment of pulmonary hypertension.
Claims16
1-10. (canceled)
A method of identifying a subject having or at risk of having or developing a pulmonary hypertension, which comprises the step of analyzing a biological sample from said subject for:
- (i) detecting the presence of a mutation in the gene encoding for CCR5 and/or its associated promoter, and/or
- (ii) determining the level of expression of the gene encoding for CCR5 or the CCR5 protein level.
(canceled)
A kit for identifying whether a subject has or is at risk of having or developing a pulmonary hypertension, which comprises means for analyzing a biological sample from said subject for:
- (i) detecting the presence of a mutation in the gene encoding for CCR5 and/or its associated promoter, and/or
- (ii) determining the level of expression of the gene encoding for CCR5 or the CCR5 protein level.
A method of preventing or treating pulmonary hypertension in a subject in need thereof, comprising the step of administering to said subject a compound which is a CCR5 antagonist and/or an inhibitor of CCR5 expression.
The method according to claim 20 wherein said CCR5 antagonist is maraviroc.
A method for inhibiting smooth muscle cell proliferation in a subject afflicted with pulmonary hypertension comprising the step of administering to said subject a compound which is a CCR5 antagonist and/or an inhibitor of CCR5 expression.
A method of preventing or treating vascular remodeling in a subject afflicted with pulmonary hypertension comprising the step of administering to said subject a compound which is a CCR5 antagonist and/or an inhibitor of CCR5 expression.
A method for monitoring the efficacy of a treatment of subject afflicted with a pulmonary hypertension, said method comprising the steps consisting of:
- a) diagnosing pulmonary hypertension by analyzing a biological sample from said subject by:
- (i) detecting the presence of a mutation in the gene encoding for CCR5 and/or its associated promoter, and/or
- (ii) determining the level of expression of the gene encoding for CCR5 or the CCR5 protein level;
- c) measuring arterial pressure of said subject
- d) treating said subject by administering to said subject a compound which is a CCR5 antagonist and/or an inhibitor of CCR5 expression;
- e) measuring arterial pressure of said subject after said step of treating and
- f) comparing results determined at step c) with the results determined at step e), wherein a difference between said results is indicative of the effectiveness of the treatment.
Dependencies are inferred from the claim text.